New: companion diagnostics

Learn more

Epigenetic assays


A large number of published papers is clearly showing that disease-related methylation changes have a huge potential as biomarkers at each stage of the clinical disease management. From early screening and diagnosis, to risk assessment in prognosis and treatment, as well as monitoring chronic diseases, epigenetic biomarkers have an important capability to contribute to personalized patient care at all levels. Therefore, disease related methylation changes are an attractive source of the biomarkers in the context of precision medicine, which is often overlooked today.

From the more than 14,000 scientific publications describing DNA methylation-based biomarkers and their clinical associations in oncology, only 14 of these biomarkers have been translated into a commercially available clinical test. Methodological and experimental obstacles are both major causes (Koch et al) and optimal assay design requires a unique expertise. The right genomic location of a DNA methylation-based biomarker is essential as well as.

At our experts educated in the labs of world leaders in epigenetic, have a track record in epigenetic assay development with proven market success. The translation of genome-wide or array based epigenetic data into robust routine proof test like MSP format, is in the core of our strengths. We can either start from your samples or from your epigenetic data to downsize the signature size.

Your epigenetic data as starting point: After intensively reviewing the data, will define the best route towards optimal robust and simplified assay development, including optimization of the current model or a de novo machine learning approach focusing on alternative algorithms and signatures.

Your samples as starting point: has a state of the art discovery platform and computational biology expertise in house for top nudge methylation profiling analysis. The optimal epigenetic biomarkers will be selected and validated against the related genes or pathways of the event in focus. Genome-wide or array based epigenetic data will be translated into simplified routine proof test like MSP formats.

A full companion diagnostic integrated solution: Our full companion diagnostic integrated solution is sample type and disorder agnostic. We like to support you in domains of oncology, neurology and infectious disease. With our experts in house, we put together an efficient companion diagnostic development program with focus on your success:


  • Biomarker discovery, selection and validation
  • Biomarker competitive strategy
  • Assay prototype building
  • Assay validation

Dedicated Team of Experts

Wim Van Criekinge

Scientific advisor

Prof. Wim Van Criekinge, together with Jan, is a co-founder of the Novalis Biotech Incubation. He is a tenured professor at the University of Gent with an interest in the use of machine learning in computational biology and bioinformatics.

Manon van Engeland

Scientific advisor

Prof. Manon van Engeland is currently attached to the Cancer Pathobiology Group of the Maastricht University. She is also member of the Early Cancer Detection Europe working group. She has been involved in the discovery of several epigenetic biomarkers for CRC, BRCA, melanoma and renal CA.

Call the expert